Matrix-M Adjuvant

BIOLOGICAL2 trials

Sponsors

Novavax

Conditions

EbolaInfluenza, Human

Phase 1

Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects

CompletedNCT02370589

Start: 2015-02-28End: 2016-04-30Updated: 2021-11-24

Phase 2

Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

TerminatedNCT03658629

NovavaxInfluenza, Human

Start: 2018-09-24End: 2019-04-26Updated: 2022-11-04

Related Papers

Induction of Cross-Reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-Cell Responses by a Recombinant Matrix-M–Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine

Clinical Infectious Diseases2020-10-2940 citations